Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 4pembrolizumab 3napabucasin 3Paclitaxel 3Irinotecan 3selpercatinib 2pralsetinib 2patritumab 2Standard of Care 2Pemetrexed 2Nivolumab 2Fluorouracil 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Ascorbic Acid 2Albumin-Bound Paclitaxel 2valrubicin 1sotorasib 1ribociclib 1relatlimab 1pamiparib 1osimertinib 1ipatasertib 1durvalumab 1dostarlimab 1cobimetinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms by Site × valrubicin × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡